Clinical research and studies

Research underpins everything we do at BIOHIT HealthCare, so that when our products come to market, they are supported by the evidence needed to offer real benefit and impact. 

We have an active research and development department headed by a scientific board comprising of experts in key areas of medicine, biochemistry and technology, who collaborate with the medical and scientific communities worldwide. We work closely with academic and clinical establishments to build robust evidence, supporting the uptake of our products and services, and helping to develop and transfer new technology for tomorrow's healthcare systems.

Study protocols

We also develop and share study protocols, i.e., descriptions of clinical studies designed for validation of our diagnostic tests, as well as for evaluation of therapeutic efficacy of BIOHIT's Acetium® capsule and lozenge products. This applies to both current and novel clinical indications.

In recent years, the UK public health sector has embraced the opportunity to collaborate more with industry. The collaborative partnership of expert-led clinical care and resources with the technologies developed and marketed by BIOHIT, has led to the discovery of new applications for diagnostic tests, as well as cutting edge research into cost-effective strategies for the future.

Got an interesting research project?

Let us know how we can collaborate. We are always looking for new ways to partner and build effective healthcare applications using our diagnostic and intervention products.

Research collaboration

We welcome the opportunity to collaborate on basic and clinical research, with a focus on developing strategies that address the priorities of national clinical needs. In 2018, for example, the research committee of the British Society of Gastroenterology launched its clinical research strategy, setting out its vision for the future in terms of priority areas for clinical research.


One of the top three priorities for the Endoscopy Clinical Research Group is to explore how minimally invasive tests can help to stratify gastrointestinal cancer risk, while the IBD Clinical Research Group focuses on ways to optimise treatment and identify markers for disease monitoring and prognosis. It is strategies such as these that we align our research resources with, highlighted by products such as our non-invasive GastroPanel blood test.

We also support specific projects that such as investigator-led research and clinical trials involving BIOHIT products and services.